ARID2 and neoplasm: It has been reported that the mutation of AT-rich interaction domain 2 (ARID2), which is a constituent of the SW1/SNF complex, might be a tumor mutation burden in HCC and may correlate with the efficacy of ICIs; however, it has not yet reached the stage of clinical application [200].